Answers are grounded in this paper and cite their sources.
Background Checkpoint inhibitor pneumonitis (CIP) is a life-threatening complication of immune checkpoint inhibitors (ICI). We aimed to identify predictive biomarkers associated with symptomatic CIP (sCIP) and unravel the underlying pathogenesis. Methods We integrated CyTOF, proteomics, single-cell RNA and V(D)J sequencing, single-cell secretomics, and spatial transcriptomics. These techniques were used to profile peripheral blood, bronchoalveolar lavage fluid, and lung tissue samples from two prospective multi-center cohorts of NSCLC patients receiving ICI combination treatments. Results Elevated serum CXCL9 levels combined with high frequencies of peripheral PD-1 + CD8 + T cells after induction ICI were associated with subsequent sCIP (AUC=0.954) and inferior overall survival (HR=7.19, p=0.004). Mechanistically, PD-1 + CD8 + T cells displayed a type 1 effector profile characterized by IFN-γ and MIP-1β secretion. CXCL9/CXCR3 signaling was associated with recruitment of these cells to inflamed lung tissue. Conclusions The CXCL9-PD-1 + CD8 + T cell axis is associated with CIP pathogenesis. This mechanism supports a potential blood-based biomarker model for CIP risk stratification and identifies a promising preventive therapeutic target to optimize clinical management.
No takes yet. Share an insight, caveat, or question.
Bi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: